Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease
- PMID: 1551637
- DOI: 10.1002/hep.1840150409
Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease
Abstract
Beneficial effects of ursodeoxycholic acid in chronic cholestatic liver diseases have been attributed to displacement of hydrophobic bile acids from the endogenous bile acid pool. To test this hypothesis, we determined pool sizes, fractional turnover rates, synthesis/input rates and serum levels of deoxycholic acid and chenodeoxycholic acid before and 1 mo after the start of treatment with ursodeoxycholic acid (13 to 15 mg/kg body wt/day) in four healthy volunteers and five patients with chronic cholestatic liver diseases (three with primary biliary cirrhosis and two with primary sclerosing cholangitis). Bile acid kinetics were determined by combined capillary gas chromatography-isotope ratio mass spectrometry in serum samples after administration of [2H4] deoxycholic acid and [13C]chenodeoxycholic acid. In healthy volunteers, deoxycholic acid pool sizes decreased during administration of ursodeoxycholic acid by 72%. In patients with cholestatic liver diseases, deoxycholic acid pool sizes before ursodeoxycholic acid treatment were only 13% of those in healthy volunteers and were unaffected by ursodeoxycholic acid treatment. Chenodeoxycholic acid pool sizes were not different in healthy volunteers and in patients with cholestatic liver disease, and were not altered by ursodeoxycholic acid treatment. In both healthy volunteers and patients with cholestatic liver disease, synthesis/input rates and serum levels of deoxycholic acid and chenodeoxycholic acid were not altered by ursodeoxycholic acid treatment. Because in our patients improvement of serum liver tests during short-term ursodeoxycholic acid treatment was noted without a decrease of the pool sizes of the major hydrophobic bile acids, we conclude that displacement of hydrophobic endogenous bile acids is not the mechanism of action of ursodeoxycholic acid in chronic cholestatic liver disease.
Similar articles
-
Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis.Hepatology. 1993 Jun;17(6):1028-32. Hepatology. 1993. PMID: 8514251
-
Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis.Dig Dis Sci. 1993 May;38(5):896-902. doi: 10.1007/BF01295917. Dig Dis Sci. 1993. PMID: 8482188
-
Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.Gastroenterology. 1994 Jan;106(1):134-42. doi: 10.1016/s0016-5085(94)94899-2. Gastroenterology. 1994. PMID: 8276175
-
Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.Ital J Gastroenterol. 1992 Jan;24(1):31-5. Ital J Gastroenterol. 1992. PMID: 1571577 Review.
-
Novel and emerging therapies for cholestatic liver diseases.Liver Int. 2018 Sep;38(9):1520-1535. doi: 10.1111/liv.13880. Epub 2018 Jun 14. Liver Int. 2018. PMID: 29758112 Review.
Cited by
-
Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis.J Clin Invest. 1993 Dec;92(6):2984-93. doi: 10.1172/JCI116921. J Clin Invest. 1993. PMID: 8254052 Free PMC article.
-
Pediatric Cholestatic Liver Disease: Review of Bile Acid Metabolism and Discussion of Current and Emerging Therapies.Front Med (Lausanne). 2020 May 5;7:149. doi: 10.3389/fmed.2020.00149. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32432119 Free PMC article. Review.
-
Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis.Gut. 1996 Mar;38(3):439-46. doi: 10.1136/gut.38.3.439. Gut. 1996. PMID: 8675100 Free PMC article. Clinical Trial.
-
Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction.Front Physiol. 2021 Jul 29;12:718783. doi: 10.3389/fphys.2021.718783. eCollection 2021. Front Physiol. 2021. PMID: 34393832 Free PMC article. Review.
-
Cholestasis-Associated Pruritus and Its Pruritogens.Front Med (Lausanne). 2021 Mar 9;8:639674. doi: 10.3389/fmed.2021.639674. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33791327 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources